Artivion Inc
NYSE:AORT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.7
29.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Artivion Inc
Artivion Inc
PP&E Net
Artivion Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Artivion Inc
NYSE:AORT
|
PP&E Net
$82.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
PP&E Net
$6.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
PP&E Net
$3.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
PP&E Net
$3.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
PP&E Net
$10.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
PP&E Net
$4.4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
29%
|
|
Artivion Inc
Glance View
In the heart of the biomedical landscape, Artivion Inc. emerges as a company fervently dedicated to extending and saving lives through advanced medical technologies. It is a principal innovator and supplier in cardiac and vascular surgery, carving its niche by providing unique products that serve critical therapeutic needs. Initially branded as CryoLife, the company redefined its mission and vision under the Artivion name post a strategic transformation, focusing on strategically enhancing its product portfolio. It crafts precision-engineered prosthetic heart valves, notably the On-X mechanical valve, which is renowned for its exceptional long-term durability and performance in reducing the need for anticoagulation therapy. Through its relentless innovation, Artivion ensures that its offerings are not only of high quality but also cost-effective, thereby widening the accessibility to life-saving technologies. This commitment to quality is underscored by their rigorous research and development efforts and regulatory compliance, ensuring every product meets global medical standards. Artivion's revenue engine is driven largely by its cardiovascular implantables and bioprosthetics used in vascular surgery, alongside tissue processing services that provide mitral, aortic, and pulmonary cardiac valves. By coupling advanced materials and sophisticated design, the organization enhances its presence in the global cardiovascular industry—serving hospitals, physicians, and patients alike. Its products are distributed through a combination of direct sales and distributor partnerships, broadening its geographical market presence from the United States to Europe, Asia, and beyond. Artivion stands not only as a supplier but as a strategic partner to clinicians, extending support and education to ensure optimal patient outcomes. Its strategic prowess in the competitive med-tech arena is an intricate mosaic of innovation, operational excellence, and a keen awareness of the pressing health challenges that afflict the global population. Through these concerted efforts, Artivion not only sustains its growth and shareholder value but continues its mission to improve life expectancy and quality around the world.
See Also
What is Artivion Inc's PP&E Net?
PP&E Net
82.2m
USD
Based on the financial report for Dec 31, 2023, Artivion Inc's PP&E Net amounts to 82.2m USD.
What is Artivion Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
22%
Over the last year, the PP&E Net growth was 2%. The average annual PP&E Net growth rates for Artivion Inc have been 17% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
